Alternative Data for Voyager Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,863 | Sign up | Sign up | Sign up |
| X Followers | 924 | Sign up | Sign up | Sign up |
| X Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 173 | Sign up | Sign up | Sign up |
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases.
| Price | $4.46 |
| Target Price | Sign up |
| Volume | 487,373 |
| Market Cap | $266M |
| Year Range | $2.96 - $5.33 |
| Dividend Yield | 0% |
| PE Ratio | 6.02 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 13M | 0 | 13M | -28M | -27M | -0.470 |
| Q2 '25 | 5.2M | 0 | 5.2M | -33M | -36M | -0.570 |
| Q1 '25 | 6.5M | 0 | 6.5M | -31M | -34M | -0.530 |
| Q4 '24 | 6.3M | 1M | 6.3M | -34M | -37M | -0.590 |
| Q3 '24 | 25M | 0 | 25M | -9M | -13M | -0.160 |
Insider Transactions View All
| Carter Todd Alfred filed to sell 145,718 shares at $3.8. February 26 '26 |
| Jorgensen Nathan D. filed to sell 151,416 shares at $3.8. February 26 '26 |
| Swartz Robin filed to sell 199,738 shares at $3.8. February 26 '26 |
| Sandrock Alfred filed to sell 484,060 shares at $3.8. February 26 '26 |
| Carter Todd Alfred filed to sell 149,892 shares at $3.4. February 20 '26 |
Similar companies
Read more about Voyager Therapeutics (VYGR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Voyager Therapeutics
The Market Cap of Voyager Therapeutics is $266M.
As of today, Voyager Therapeutics' PE (Price to Earnings) ratio is 6.02.
Currently, the price of one share of Voyager Therapeutics stock is $4.46.
The VYGR stock price chart above provides a comprehensive visual representation of Voyager Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Voyager Therapeutics shares. Our platform offers an up-to-date VYGR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Voyager Therapeutics (VYGR) does not offer dividends to its shareholders. Investors interested in Voyager Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Voyager Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
